Biohaven Pharmaceutical Hold
13F holders, Q4 2025 (December 31)2holders
1new positions
1sold out
$11.29avg. 13F price*
At the end of Q4 2025, 2 institutions reported holding Biohaven Pharmaceutical Hold in their 13F filings, unchanged from Q3 2025. 1 opened new positions and 1 sold out. The largest holders were Knoll Capital Management, LLC ($26.3M) and Birchview Capital, LP ($670K).
- Company
- Biohaven Pharmaceutical Hold
- CUSIP
- G11196105
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q3 2025 → Q4 2025
| Institutions | Total Value | |
|---|---|---|
| New Positions | 1 | $670K |
| Exits | 1 | $34K |
All 13F filers, Q3 2025 → Q4 2025: 1,492,698 shares bought and 2,300 shares sold, net +1,490,398 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 2 holders
| Knoll Capital Management, LLC | 12.06% | Add +160.1% | 2,328,602 | $26.3M |
| Birchview Capital, LP | 0.39% | New | 59,365 | $670K |
"% of holder's portfolio" is BIOHAVEN PHARMACEUTICAL HOLD's weight in each manager's 13F, not the share of Biohaven Pharmaceutical Hold the manager owns.